Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

23.00
Delayed Data
As of Dec 09
 +0.70 / +3.14%
Today’s Change
9.51
Today|||52-Week Range
26.84
+71.13%
Year-to-Date
What's in the Cards for Nutanix (NTNX) in Q1 Earnings?
Nov 28 / Zacks.com - Paid Partner Content
What's in the Cards for Box, Inc. (BOX) in Q3 Earnings?
Nov 28 / Zacks.com - Paid Partner Content
Top Ranked Income Stocks to Buy for November 28th
Nov 28 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close22.30
Today’s open22.50
Day’s range22.45 - 23.20
Volume649,843
Average volume (3 months)628,964
Market cap$1.1B
Dividend yield--
Data as of 4:00pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)-12.50%
Earnings growth (this year)+190.00%
Earnings growth (next 5 years)+50.00%
Revenue growth (last year)+18.34%
P/E ratio46.0
Price/Sales4.76
Price/Book9.48

Competitors

 Today’s
change
Today’s
% change
ALDRAlder Biopharmaceuti...+0.90+4.20%
AIMTAimmune Therapeutics...-0.01-0.04%
EGRXEagle Pharmaceutical...-0.72-0.94%
INVAInnoviva Inc+0.03+0.28%
Data as of 4:00pm ET, 12/09/2016

Financials

Next reporting dateMarch 8, 2017
EPS forecast (this quarter)$0.22
Annual revenue (last year)$144.4M
Annual profit (last year)$14.0M
Net profit margin9.70%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, CEO, Director &
Secretary
Jack A. Khattar
CFO, Vice President &
Head-Investor Relations
Gregory S. Patrick
Corporate headquarters
Rockville, Maryland

Forecasts


Search for Jobs